Originator companies and generic/biosimilar companies in the (bio)pharmaceutical industry are working more and more with different biological materials of animal or human origin. Cell lines from bacteria, plants, animal and/or humans as well as viruses are used in the development and manufacturing of modern (bio)pharmaceutical products. This brings also new hazards (biohazards) into the work-areas where these biological materials are handled.

For classical pharmaceutical products, good manufacturing practice (GMP) ensures that pharmaceutical products are manufactured consistently and in a controlled way according to appropriate quality standards. Regulatory agencies worldwide require to meet GMP guidelines from producers and sellers of pharmaceutical products.

But now, as described above, some specific products such as certain vaccines or products derived from genetically modified organisms (GMOs) require complete different guidelines. This fact is also valid for biologics, biopharmaceuticals, biosimilars and advanced therapy medicinal products (ATMPs). The respective guidelines are summarized under the term biosafety. Biosafety defines the conditions, techniques and equipment used to prevent personal, laboratory and environmental exposure to potentially infectious or harmful agents. Depending on the risk class of these agents, manipulations with them have to be carried out in BSL1 to BSL4 laboratories (demanding increasing safety measures).

In certain cases, it might come to clashes between GMP requirements and biosafety. GMP guidelines, which have the product safety in their focus, demand the “keep out” principle to protect the product whereas biosafety often requires the “keep in” principle to protect the employees and environment. Starting from BSL2, safety of employees and environment generally overrules product safety. In this case, a defined risk assessment is necessary in order to find an alternative way to fulfill all GMP requirements and have patients/operator safety in perspective.

VelaLabs, a member of Tentamus Pharma Group, is well experienced in the field of biosafety laws including handling and storage of GMOs. Thus, VelaLabs is one of the few laboratories worldwide, which can support your analytical testing requirements in a combination of GMP and BSL2 conditions.

Contact our experts for further information.

Über die Tentamus Group GmbH

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrochemicals, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 52 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.

Firmenkontakt und Herausgeber der Meldung:

Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com

Ansprechpartner:
Dr. Gerald Hofer
Director Sales / Business Development at Tentamus Group GmbH
Telefon: +43 (699) 131431-60
E-Mail: gerald.hofer@tentamus.com
Dr. Markus Fido
CEO Vela Labs
E-Mail: m.fido@vela-labs.at
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel